Jeffrey Schlom

List of Publications by Year in Descending Order

343 papers	19,052 citations	71 h-index	125 g-index
354 ext. papers	21,786 ext. citations	6.3 avg, IF	6.57 L-index

#	Paper	IF	Citations
343	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.. *Oncologist*, **2022**, 27, 198-209	5.7	0
342	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).. *Prostate Cancer and Prostatic Diseases*, **2022**,	6.2	2
341	Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.. *Oncologist*, **2022**, 27, e353-e356	5.7	1
340	Peptide-based vaccines **2022**, 155-173		
339	The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study.. *Journal of Clinical Oncology*, **2022**, 40, 127-127	2.2	0
338	Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.. *Journal of Clinical Oncology*, **2022**, 40, 249-249	2.2	
337	Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. *Journal of Clinical Oncology*, **2022**, 40, 130-130	2.2	1
336	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. *Journal of Clinical Oncology*, **2022**, 40, 93-93	2.2	0
335	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.. *JCI Insight*, **2022**, 7,	9.9	1
334	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.. *Experimental Biology and Medicine*, **2022**, 15353702221089910	3.7	0
333	Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. *Cancer Immunology Research*, **2021**, 9, 239-252	12.5	5
332	Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. *Molecular Oncology*, **2021**,	7.9	1
331	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer **2021**, 9,		2
330	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) **2021**, 9,		10
329	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic **2021**, 9,		1
328	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells **2021**, 9,		7
327	Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009. *JCI Insight* , **2021**, 6,	9.9	7

326	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. *Journal of Clinical Oncology*, **2021**, 39, 2617-2617	2.2	
325	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.. *Journal of Clinical Oncology*, **2021**, 39, 2501-2501	2.2	3
324	NHS-IL12, a Tumor-Targeting Immunocytokine. *ImmunoTargets and Therapy*, **2021**, 10, 155-169	9	5
323	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. *Journal of Clinical Oncology*, **2021**, 39, TPS4599-TPS4599	2.2	1
322	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, TPS5096-TPS5096	2.2	1
321	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. *Journal of Clinical Oncology*, **2021**, 39, TPS6092-TPS6092	2.2	2
320	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. *Npj Vaccines*, **2021**, 6, 86	9.5	0
319	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy **2021**, 9,		2
318	Immunology of Lynch Syndrome. *Current Oncology Reports*, **2021**, 23, 96	6.3	2
317	Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing **2021**, 9,		3
316	Combination therapies utilizing neoepitope-targeted vaccines. *Cancer Immunology, Immunotherapy*, **2021**, 70, 875-885	7.4	6
315	Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. *OncoImmunology*, **2021**, 10, 1915561	7.2	2
314	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. *Cancers*, **2021**, 13,	6.6	5
313	Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve **2021**, 9,		5
312	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. *Oncologist*, **2021**, 26, e847-e858	5.7	9
311	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. *Nature Communications*, **2021**, 12, 5151	17.4	5
310	Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis **2021**, 9,		2
309	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer **2021**, 9,		3

308	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.. *Journal of Cancer Prevention*, **2021**, 26, 309-317	3	
307	Overcoming hypoxia-induced functional suppression of NK cells **2020**, 8,		22
306	The Use of a Humanized NSG-2m Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa. *Frontiers in Oncology*, **2020**, 10, 549	5.3	9
305	Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine **2020**, 8,		22
304	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. *Oncologist*, **2020**, 25, 560-e1006	5.7	10
303	Dual targeting of TGF-and PD-L1 via a bifunctional anti-PD-L1/TGF-RII agent: status of preclinical and clinical advances **2020**, 8,		92
302	Simultaneous inhibition of CXCR1/2, TGF-and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity **2020**, 8,		32
301	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer **2020**, 8,		21
300	Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist **2020**, 8,		9
299	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations **2020**, 8,		40
298	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. *Journal of Clinical Oncology*, **2020**, 38, 11527-11527	2.2	4
297	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. *ELife*, **2020**, 9,	8.9	19
296	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. *Oncologist*, **2020**, 25, 479-e899	5.7	23
295	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. *Clinical Cancer Research*, **2020**, 26, 704-716	12.9	12
294	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. *Clinical Cancer Research*, **2020**, 26, 1420-1431	12.9	67
293	The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. *Anticancer Research*, **2020**, 40, 5329-5341	2.3	12
292	The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19. *Journal of Infectious Diseases*, **2020**, 222, 1435-1438	7	
291	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management **2020**, 8,		8

290	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. *Frontiers in Endocrinology*, **2020**, 11, 490	5.7	5
289	Therapeutic Vaccines for HPV-Associated Malignancies. *ImmunoTargets and Therapy*, **2020**, 9, 167-200	9	19
288	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-and PD-L1, in patients with human papillomavirus-associated malignancies **2020**, 8,		21
287	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. *Frontiers in Oncology*, **2020**, 10, 581801	5.3	4
286	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors **2019**, 7, 240		85
285	Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. *Oral Oncology*, **2019**, 90, 38-44	4.4	14
284	Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12 **2019**, 7, 150		11
283	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. *Clinical Cancer Research*, **2019**, 25, 4933-4944	12.9	27
282	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis **2019**, 7, 119		15
281	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy **2019**, 7, 82		45
280	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. *Clinical Cancer Research*, **2019**, 25, 99-109	12.9	71
279	Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. *Cancer Immunology Research*, **2019**, 7, 1359-1370	12.5	18
278	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma **2019**, 7, 269		43
277	Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies **2019**,		12
276	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. *JCI Insight*, **2019**, 4,	9.9	95
275	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. *JCI Insight*, **2019**, 4,	9.9	17
274	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. *Annals of the Rheumatic Diseases*, **2019**, 78, 150-152	2.4	56
273	The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. *OncoImmunology*, **2019**, 8, e1532764	7.2	15

272	An IL-15 superagonist/IL-15R Fusion complex protects and rescues NK cell-cytotoxic function from TGF-1-mediated immunosuppression. *Cancer Immunology, Immunotherapy*, **2018**, 67, 675-689	7.4	33
271	M7824, a novel bifunctional anti-PD-L1/TGF Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. *OncoImmunology*, **2018**, 7, e1426519	7.2	109
270	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF in Advanced Solid Tumors. *Clinical Cancer Research*, **2018**, 24, 1287-1295	12.9	195
269	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial). *Human Pathology*, **2018**, 78, 72-78	3.7	1
268	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 1259-1270	4	34
267	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. *Journal of Neurosurgery*, **2018**, 128, 1419-1427	3.2	10
266	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies **2018**, 6, 59		29
265	Immunotherapy for biochemically recurrent prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 215-215	2.1	5
264	Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.. *Journal of Clinical Oncology*, **2018**, 36, 5021-5021	2.2	
263	Anti-PD-L1/TGFR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 93.e1-93.e11	2.8	23
262	EXTH-63. EFFICIENT ADCC-MEDIATED KILLING OF MALIGNANT MENINGIOMA CELLS USING AVELUMAB AND AN ENGINEERED HIGH AVIDITY NATURAL KILLER CELL LINE, haNK. *Neuro-Oncology*, **2018**, 20, vi98-vi98	1	78
261	Vaccines as an Integral Component of Cancer Immunotherapy. *JAMA - Journal of the American Medical Association*, **2018**, 320, 2195-2196	27.4	18
260	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. *European Urology Focus*, **2018**, 4, 636-638	5.1	8
259	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations **2018**, 6, 141		132
258	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. *OncoImmunology*, **2018**, 7, e1466018	7.2	32
257	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody **2017**, 5, 20		57
256	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. *International Journal of Cancer*, **2017**, 141, 583-593	7.5	27
255	Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. *Vaccine*, **2017**, 35, 2605-2611	4.1	14

254	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. *Lancet Oncology, The*, **2017**, 18, 587-598	21.7	194
253	Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer. *Oncotarget*, **2017**, 8, 90825-90841	3.3	11
252	A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. *OncoImmunology*, **2017**, 6, e1349589	7.2	91
251	Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer **2017**, 5, 22		136
250	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. *Clinical Cancer Research*, **2017**, 23, 6833-6845	12.9	39
249	Abstract 594: Dual targeting of TGFb and PD-L1 promotes potent anti-tumor efficacy in multiple murine models of solid carcinomas **2017**,		5
248	Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β in advanced solid tumors.. *Journal of Clinical Oncology*, **2017**, 35, 3006-3006	2.2	15
247	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. *Oncotarget*, **2017**, 8, 8807-8817	3.3	51
246	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. *Oncotarget*, **2017**, 8, 20558-20571	3.3	34
245	Analyses of functions of an anti-PD-L1/TGFBR2 bispecific fusion protein (M7824). *Oncotarget*, **2017**, 8, 75217-75231	3.3	33
244	Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein. *Oncotarget*, **2017**, 8, 73469-73482	3.3	6
243	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. *Oncotarget*, **2016**, 7, 33498-511	3.3	70
242	Malignant Mesothelioma Effusions Are Infiltrated by CD3 T Cells Highly Expressing PD-L1 and the PD-L1 Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. *Journal of Thoracic Oncology*, **2016**, 11, 1993-2005	8.9	77
241	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. *Journal of Circulating Biomarkers*, **2016**, 5, 5	3.3	34
240	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. *OncoImmunology*, **2016**, 5, e1188243	7.2	20
239	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. *Cancer Immunology Research*, **2016**, 4, 452-62	12.5	62
238	Abstract 1480: Systemic immunotherapeutic efficacy of an immunocytokine, NHS-muIL12, in a superficial murine orthotopic bladder cancer model **2016**,		2
237	Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. *Journal of Clinical Oncology*, **2016**, 34, e20106-e20106	2.2	6

236	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. *Oncotarget*, **2016**, 7, 69014-69023	3.3	31
235	IL-15 superagonist/IL-15Rαsushi-Fc fusion complex (IL-15SA/IL-15Rαsu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. *Oncotarget*, **2016**, 7, 16130-45	3.3	102
234	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. *Oncotarget*, **2016**, 7, 37762-37772	3.3	76
233	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. *Oncotarget*, **2016**, 7, 86359-86373	3.3	99
232	A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. *Clinical and Translational Immunology*, **2016**, 5, e83	6.8	38
231	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α2b in patients with CEA-expressing carcinomas. *Cancer Immunology, Immunotherapy*, **2016**, 65, 1353-1364	7.4	19
230	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. *Cancer Immunology Research*, **2016**, 4, 755-65	12.5	25
229	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. *Cancer Immunology Research*, **2015**, 3, 1248-56	12.5	89
228	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. *Cancer Immunology, Immunotherapy*, **2015**, 64, 1429-35	7.4	2
227	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. *Cancer Immunology Research*, **2015**, 3, 1148-1157	12.5	281
226	Insights on Peptide Vaccines in Cancer Immunotherapy. *Cancer Drug Discovery and Development*, **2015**, 1-27	0.3	2
225	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. *JAMA Oncology*, **2015**, 1, 1087-95	13.4	58
224	Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells.. *Journal of Clinical Oncology*, **2015**, 33, 3038-3038	2.2	2
223	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. *Journal of Clinical Oncology*, **2015**, 33, 3055-3055	2.2	14
222	The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro.. *Journal of Clinical Oncology*, **2015**, 33, e14012-e14012	2.2	1
221	Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, TPS5081-TPS5081	2.2	4
220	Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2015**, 33, 597-597	2.2	1
219	Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. *Oncotarget*, **2015**, 6, 4853-62	3.3	21

218	ABO blood type correlates with survival on prostate cancer vaccine therapy. *Oncotarget*, **2015**, 6, 32244-56	3.9	12
217	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. *Oncotarget*, **2015**, 6, 31344-59	3.3	24
216	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, e14008-e14008	2.2	1
215	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. *Cancer Immunology, Immunotherapy*, **2014**, 63, 225-34	7.4	70
214	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. *Cancer Immunology, Immunotherapy*, **2014**, 63, 161-74	7.4	21
213	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E1749-58	11.5	36
212	Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	59
211	Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. *Cancer Immunology, Immunotherapy*, **2014**, 63, 1307-17	7.4	22
210	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. *International Journal of Cancer*, **2014**, 135, 862-70	7.5	4
209	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. *Cancer Immunology Research*, **2014**, 2, 133-41	12.5	93
208	Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. *Cancer Research*, **2014**, 74, 1945-57	10.1	30
207	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. *Journal of Translational Medicine*, **2014**, 12, 122	8.5	13
206	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. *Cancer Immunology, Immunotherapy*, **2014**, 63, 407-18	7.4	71
205	The immunocytokine NHS-IL12 as a potential cancer therapeutic. *Oncotarget*, **2014**, 5, 1869-84	3.3	82
204	Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. *Journal of Immunology*, **2014**, 192, 2622-33	5.3	21
203	Therapeutic cancer vaccines. *Advances in Cancer Research*, **2014**, 121, 67-124	5.9	49
202	Potential utility of the pan-Bcl-2 inhibitor GX15-070 (obatoclax) in cancer immunotherapy. *OncoImmunology*, **2014**, 3, e29351	7.2	4
201	The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors **2014**, 315-334		

200	Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.. *Journal of Clinical Oncology*, **2014**, 32, 3064-3064	2.2	21
199	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. *Journal of Clinical Oncology*, **2014**, 32, 3081-3081	2.2	5
198	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 4501-4501	2.2	21
197	A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, e14026-e14026	2.2	2
196	A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.. *Journal of Clinical Oncology*, **2014**, 32, TPS4590-TPS4590	2.2	5
195	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer **2014**, 291-327		1
194	Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees. *Expert Review of Vaccines*, **2013**, 12, 1121-4	5.2	2
193	Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned **2013**, 309-331		1
192	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 1521-31	7.4	31
191	Serum antibodies to blood group A predict survival on PROSTVAC-VF. *Clinical Cancer Research*, **2013**, 19, 1290-9	12.9	43
190	Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. *Oncologist*, **2013**, 18, 821-2	5.7	8
189	Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. *International Journal of Cancer*, **2013**, 133, 373-82	7.5	23
188	Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. *Journal of Immunology*, **2013**, 190, 6250-8	5.3	45
187	The role of soluble CD40L in immunosuppression. *OncoImmunology*, **2013**, 2, e22546	7.2	18
186	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. *OncoImmunology*, **2013**, 2, e27025	7.2	105
185	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. *Journal of Clinical Oncology*, **2013**, 31, 102-102	2.2	13
184	Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. *Oncotarget*, **2013**, 4, 1777-90	3.3	57
183	Safety profile of poxviral vaccines: NCI experience.. *Journal of Clinical Oncology*, **2013**, 31, 85-85	2.2	

182	Introduction: Therapeutic cancer vaccines. *Seminars in Oncology*, **2012**, 39, 243-4	5.5	
181	Clinical evaluation of TRICOM vector therapeutic cancer vaccines. *Seminars in Oncology*, **2012**, 39, 296-304	5.5	68
180	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. *Blood*, **2012**, 120, 3030-8	2.2	81
179	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. *Lancet Oncology, The*, **2012**, 13, 501-8	21.7	299
178	Therapeutic cancer vaccines: current status and moving forward. *Journal of the National Cancer Institute*, **2012**, 104, 599-613	9.7	207
177	Recent advances in therapeutic cancer vaccines. *Cancer Biotherapy and Radiopharmaceuticals*, **2012**, 27, 2-5	3.9	10
176	Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. *Cancers*, **2012**, 4, 1333-48	6.6	4
175	Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. *Clinical Cancer Research*, **2012**, 18, 3868-79	12.9	93
174	Distinct effects of saracatinib on memory CD8+ T cell differentiation. *Journal of Immunology*, **2012**, 188, 4323-33	5.3	11
173	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. *Journal of Clinical Oncology*, **2012**, 30, 2526-2526	2.2	8
172	Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. *Vaccine*, **2011**, 29, 4992-9	4.1	17
171	Viral vector-based therapeutic cancer vaccines. *Cancer Journal (Sudbury, Mass)*, **2011**, 17, 359-71	2.2	115
170	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. *Cancer Immunology, Immunotherapy*, **2011**, 60, 197-206	7.4	47
169	Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. *Experimental Biology and Medicine*, **2011**, 236, 567-79	3.7	215
168	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. *Expert Opinion on Biological Therapy*, **2011**, 11, 1409-18	5.4	20
167	A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. *Clinical Cancer Research*, **2011**, 17, 7164-73	12.9	95
166	The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 182413		7
165	IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 454861		12

164	Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. *Experimental Biology and Medicine*, **2011**, 236, 537-45	3.7	27
163	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, **2010**, 28, 1099-105	2.2	786
162	A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. *Clinical Cancer Research*, **2010**, 16, 4046-56	12.9	45
161	Vaccines against human carcinomas: strategies to improve antitumor immune responses. *Journal of Biomedicine and Biotechnology*, **2010**, 2010, 380697		35
160	Strategies for cancer vaccine development. *Journal of Biomedicine and Biotechnology*, **2010**, 2010,		80
159	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. *Expert Opinion on Biological Therapy*, **2010**, 10, 19-28	5.4	26
158	The MUC1-C oncoprotein as a target in hematologic malignancies. *Cancer Biology and Therapy*, **2010** , 10, 492-4	4.6	3
157	The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. *Journal of Clinical Investigation*, **2010**, 120, 533-44	15.9	199
156	Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. *Journal of Immunotherapy*, **2010**, 33, 697-705	5	57
155	New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. *Cancer Immunology, Immunotherapy*, **2010**, 59, 63-71	7.4	23
154	Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. *Cancer Immunology, Immunotherapy*, **2010**, 59, 397-408	7.4	34
153	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. *Cancer Immunology, Immunotherapy*, **2010**, 59, 663-74	7.4	249
152	Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. *Cancer Immunology, Immunotherapy*, **2010**, 59, 1247-58	7.4	24
151	Vaccines as monotherapy and in combination therapy for prostate cancer. *Clinical and Translational Science*, **2010**, 3, 116-22	4.9	9
150	Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. *International Journal of Cancer*, **2010**, 127, 1603-13	7.5	35
149	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches **2010**, 305-319		
148	Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. *Cancer Research*, **2009**, 69, 6192-9	10.1	79
147	Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. *Cancer Immunology, Immunotherapy*, **2009**, 58, 503-15	7.4	6

146	Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. *Cancer Immunology, Immunotherapy*, **2009**, 58, 955-65	7.4	16
145	TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. *Cancer Immunology, Immunotherapy*, **2009**, 58, 1809-18	7.4	23
144	Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. *Vaccine*, **2009**, 27, 987-94	4.1	41
143	Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. *Vaccine*, **2009**, 27, 4475-82	4.1	25
142	Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. *Vaccine*, **2008**, 26, 509-21	4.1	56
141	Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. *Clinical Cancer Research*, **2008**, 14, 3536-44	12.9	177
140	Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. *Clinical Cancer Research*, **2008**, 14, 4526-31	12.9	121
139	Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. *Journal of Immunology*, **2008**, 180, 5871-81	5.3	25
138	Paradigm shifts in cancer vaccine therapy. *Experimental Biology and Medicine*, **2008**, 233, 522-34	3.7	39
137	The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. *Clinical Cancer Research*, **2008**, 14, 4241-9	12.9	54
136	Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. *Clinical Cancer Research*, **2008**, 14, 4316-25	12.9	66
135	Translational Research Working Group developmental pathway for immune response modifiers. *Clinical Cancer Research*, **2008**, 14, 5692-9	12.9	29
134	Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. *Clinical Cancer Research*, **2008**, 14, 5284-91	12.9	99
133	Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. *Clinical Cancer Research*, **2008**, 14, 3060-9	12.9	181
132	Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. *Clinical Cancer Research*, **2008**, 14, 1032-40	12.9	120
131	Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1173-83	7.4	34
130	Clinical safety of a viral vector based prostate cancer vaccine strategy. *Journal of Urology*, **2007**, 178, 1515-20	2.5	109
129	Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). *International Journal of Cancer*, **2007**, 121, 595-605	7.5	18

128	Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. *Clinical Genitourinary Cancer*, **2007**, 5, 347-50	3.3	10
127	The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1471-84	7.4	32
126	Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1897-910	7.4	17
125	Cancer vaccines: moving beyond current paradigms. *Clinical Cancer Research*, **2007**, 13, 3776-82	12.9	186
124	The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. *Clinical Cancer Research*, **2007**, 13, 2471-8	12.9	123
123	Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis. *Blood*, **2007**, 109, 2488-95	2.2	15
122	Chitosan solution enhances the immunoadjuvant properties of GM-CSF. *Vaccine*, **2007**, 25, 8673-86	4.1	50
121	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. *Blood*, **2007**, 110, 3192-201	2.2	164
120	Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. *Critical Reviews in Immunology*, **2007**, 27, 451-62	1.8	39
119	Recombinant Viral and Bacterial Vaccines **2007**, 217-250		
118	TRICOM vector based cancer vaccines. *Current Pharmaceutical Design*, **2006**, 12, 351-61	3.3	45
117	Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. *Clinical Cancer Research*, **2006**, 12, 1897-905	12.9	76
116	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *Journal of Experimental Medicine*, **2006**, 203, 1259-71	16.6	1110
115	A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. *Clinical Cancer Research*, **2006**, 12, 1260-9	12.9	251
114	4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. *Vaccine*, **2006**, 24, 4975-86	4.1	32
113	Minimizing the immunogenicity of antibodies for clinical application. *Tumor Biology*, **2005**, 26, 31-43	2.9	32
112	Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. *Journal of Urology*, **2005**, 174, 539-46	2.5	97
111	SDR grafting--a new approach to antibody humanization. *Methods*, **2005**, 36, 25-34	4.6	51

110	Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. *Blood*, **2005**, 105, 2862-8	2.2	720
109	Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs. *Blood*, **2005**, 105, 3238-46	2.2	35
108	Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. *Blood*, **2005**, 106, 3515-23	2.2	26
107	The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. *Clinical Cancer Research*, **2005**, 11, 4533-44	12.9	71
106	Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. *Clinical Cancer Research*, **2005**, 11, 3353-62	12.9	323
105	Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. *Clinical Cancer Research*, **2005**, 11, 1597-607	12.9	38
104	Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. *Clinical Cancer Research*, **2005**, 11, 6342-51	12.9	51
103	Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. *Clinical Cancer Research*, **2005**, 11, 5603-15	12.9	36
102	Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. *Clinical Cancer Research*, **2005**, 11, 2416-26	12.9	70
101	Multiple costimulatory modalities enhance CTL avidity. *Journal of Immunology*, **2005**, 174, 5994-6004	5.3	122
100	Vaccines with enhanced costimulation maintain high avidity memory CTL. *Journal of Immunology*, **2005**, 175, 3715-23	5.3	45
99	Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. *Journal of Clinical Oncology*, **2005**, 23, 720-31	2.2	255
98	Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. *Journal of Clinical Oncology*, **2004**, 22, 2122-32	2.2	202
97	Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. *Cancer Research*, **2004**, 64, 7985-94	10.1	410
96	Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. *Clinical Cancer Research*, **2004**, 10, 1090-9	12.9	35
95	A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. *Clinical Cancer Research*, **2004**, 10, 2139-49	12.9	57
94	External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. *Cancer Research*, **2004**, 64, 4328-37	10.1	368
93	Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. *Cancer Gene Therapy*, **2004**, 11, 665-80	5.4	33

92	Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. *Cancer Research*, **2004**, 64, 3668-78	10.1	75
91	SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. *Molecular Immunology*, **2004**, 41, 863-72	4.3	45
90	Pox Viral Vaccines **2004**, 175-191		
89	Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL.. *Blood*, **2004**, 104, 2516-2516	2.2	
88	Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. *Expert Review of Vaccines*, **2003**, 2, 483-93	5.2	9
87	General keynote: vaccine strategies for the therapy of ovarian cancer. *Gynecologic Oncology*, **2003**, 88, S97-104; discussion S110-3	4.9	11
86	A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. *Journal of Immunological Methods*, **2003**, 279, 183-92	2.5	5
85	Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. *Cytokine*, **2003**, 24, 128-42	4	12
84	Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. *Molecular Immunology*, **2003**, 40, 337-49	4.3	21
83	Selective induction of high avidity CTL by altering the balance of signals from APC. *Journal of Immunology*, **2003**, 170, 2523-30	5.3	116
82	Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide. *Clinical Cancer Research*, **2003**, 9, 1616-27	12.9	6
81	Vaccine therapy of established tumors in the absence of autoimmunity. *Clinical Cancer Research*, **2003**, 9, 1837-49	12.9	73
80	Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. *Cancer Research*, **2003**, 63, 7942-9	10.1	48
79	In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. *Clinical Cancer Research*, **2003**, 9, 5521-31	12.9	18
78	Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies. *Journal of Immunological Methods*, **2002**, 268, 197-210	2.5	43
77	Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. *Cancer Detection and Prevention*, **2002**, 26, 275-91		16
76	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. *Prostate*, **2002**, 53, 109-17	4.2	193
75	Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. *Journal of Immunology*, **2002**, 169, 3076-84	5.3	33

74	Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. *Journal of Immunology*, **2002**, 169, 6162-9	5.3	75
73	Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. *Clinical Cancer Research*, **2002**, 8, 41-53	12.9	60
72	Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. *Cancer Research*, **2002**, 62, 5058-64	10.1	31
71	Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. *Cancer Research*, **2002**, 62, 5770-7	10.1	69
70	Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. *Cancer Research*, **2002**, 62, 6944-51	10.1	73
69	Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. *Critical Reviews in Oncology/Hematology*, **2001**, 39, 43-57	7	11
68	Acquisition of CD80 (B7-1) by T cells. *Journal of Immunology*, **2001**, 166, 2505-13	5.3	85
67	Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. *Vaccine*, **2001**, 19, 3552-67	4.1	35
66	Clinical trial designs for the early clinical development of therapeutic cancer vaccines. *Journal of Clinical Oncology*, **2001**, 19, 1848-54	2.2	98
65	Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. *International Journal of Cancer*, **2000**, 85, 508-17	7.5	8
64	Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. *International Journal of Cancer*, **2000**, 85, 829-38	7.5	61
63	Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. *Current Opinion in Immunology*, **2000**, 12, 85-91	7.8	19
62	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. *Cancer Immunology, Immunotherapy*, **2000**, 49, 517-29	7.4	68
61	Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. *Cancer Immunology, Immunotherapy*, **2000**, 49, 504-14	7.4	184
60	Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. *Journal of Clinical Oncology*, **2000**, 18, 3964-73	2.2	307
59	Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. *Journal of Immunology*, **2000**, 164, 1432-41	5.3	53
58	Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). *Human Gene Therapy*, **1999**, 10, 1095-103	4.8	58
57	Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus. *Human Gene Therapy*, **1999**, 10, 623-31	4.8	23

56	The diversity of T-cell co-stimulation in the induction of antitumor immunity. *Immunological Reviews*, **1999**, 170, 73-84	11.3	27
55	Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. *Cellular Immunology*, **1999**, 194, 78-89	4.4	15
54	CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. *Molecular Immunology*, **1999**, 36, 1079-91	4.3	26
53	A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. *Journal of Immunotherapy*, **1999**, 22, 155-65	5	99
52	Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. *Cellular Immunology*, **1998**, 187, 103-16	4.4	26
51	In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. *European Journal of Nuclear Medicine and Molecular Imaging*, **1998**, 25, 471-80	8.8	17
50	Cancer vaccine development. *Expert Opinion on Investigational Drugs*, **1998**, 7, 1439-52	5.9	2
49	Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. *Human Gene Therapy*, **1997**, 8, 851-60	4.8	45
48	Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. *Journal of Immunotherapy*, **1997**, 20, 449-59	5	25
47	Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. *Gynecologic Oncology*, **1997**, 65, 94-101	4.9	150
46	In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. *Journal of the National Cancer Institute*, **1997**, 89, 293-300	9.7	201
45	Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. *Vaccine*, **1997**, 15, 759-68	4.1	145
44	Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. *Cellular Immunology*, **1997**, 182, 137-51	4.4	74
43	Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. *International Journal of Cancer*, **1997**, 72, 949-54	7.5	43
42	Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. *Breast Cancer Research and Treatment*, **1996**, 38, 27-39	4.4	33
41	Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. *European Journal of Immunology*, **1996**, 26, 435-43	6.1	52
40	Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. *Human Gene Therapy*, **1996**, 7, 1381-94	4.8	45
39	Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. *Hybridoma*, **1995**, 14, 461-73		58

38	CA 72-4 serum marker--a new tool in the management of carcinoma patients. *Cancer Investigation*, **1995**, 13, 227-38	2.1	37
37	Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. *European Journal of Immunology*, **1995**, 25, 2588-97	6.1	38
36	A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. *International Journal of Cancer*, **1995**, 63, 231-7	7.5	87
35	Generation, purification, and characterization of a recombinant source of human prostate-specific antigen. *Journal of Clinical Laboratory Analysis*, **1995**, 9, 261-8	3	12
34	Potential for recombinant immunoglobulin constructs in the management of carcinoma. *Cancer*, **1994**, 73, 1105-13	6.4	14
33	Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. *Cancer*, **1994**, 73, 993-8	6.4	31
32	Monoclonal antibody gene transfer. Implications for tumor-specific cell-mediated cytotoxicity. *Annals of the New York Academy of Sciences*, **1994**, 716, 154-65; discussion 165-6	6.5	3
31	Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. *Journal of Immunotherapy*, **1994**, 16, 275-82	5	20
30	Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. *International Journal of Cancer*, **1993**, 53, 892-7	7.5	34
29	TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. *Cancer*, **1993**, 72, 2098-106	6.4	44
28	Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. *International Journal of Cancer*, **1993**, 53, 97-103	7.5	41
27	Crystallographic studies and primary structure of the antitumor monoclonal CC49 FabQ*Proteins: Structure, Function and Bioinformatics*, **1993**, 17, 438-43	4.2	3
26	Carcinoembryonic antigen regulation in human colorectal tumor cells by a site-selective cyclic AMP analogue: a comparison with interferon-gamma. *International Journal of Cancer*, **1991**, 48, 413-22	7.5	11
25	A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). *International Journal of Cancer*, **1991**, 48, 900-7	7.5	64
24	Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. *Cancer*, **1991**, 68, 2443-50	6.4	33
23	Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas. *Journal of Surgical Oncology*, **1991**, 2, 9-13	2.8	7
22	Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients. *Journal of Surgical Oncology*, **1991**, 2, 16-20	2.8	8
21	Monoclonal antibodies in the management of carcinoma patients. *Medical Oncology and Tumor Pharmacotherapy*, **1991**, 8, 223-8		

20	Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612. *International Journal of Cancer*, **1990**, 46, 1021-8	7.5	7
19	Assay for the detection of anti-idiotypic antibodies to monoclonal antibody B72.3. *Journal of Clinical Laboratory Analysis*, **1990**, 4, 465-73	3	4
18	mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients. *Journal of the National Cancer Institute*, **1989**, 81, 1165-71	9.7	39
17	Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. *International Journal of Cancer*, **1989**, 44, 208-18	7.5	44
16	CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients. *Journal of Clinical Laboratory Analysis*, **1989**, 3, 360-9	3	58
15	Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization. *International Journal of Cancer*, **1988**, 42, 352-8	7.5	37
14	Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. *International Journal of Cancer*, **1988**, 42, 681-6	7.5	26
13	Applications of immunocytochemistry to clinical cytology. *Cancer Investigation*, **1987**, 5, 593-611	2.1	19
12	Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms. *Vigiliae Christianae*, **1987**, 53, 146-52	0.2	25
11	ras oncogene p21 as a tumor marker in the cytodiagnosis of gastric and colonic carcinomas. *Cancer*, **1987**, 60, 2432-6	6.4	27
10	Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. *International Journal of Cancer*, **1987**, 40, 726-33	7.5	47
9	A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. *International Journal of Cancer*, **1986**, 37, 659-66	7.5	54
8	Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products. *International Journal of Cancer*, **1986**, 38, 587-95	7.5	7
7	Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. *International Journal of Cancer*, **1986**, 38, 643-50	7.5	46
6	Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). *International Journal of Cancer*, **1986**, 38, 661-9	7.5	69
5	Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. *Breast Cancer Research and Treatment*, **1985**, 6, 49-56	4.4	24
4	Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. *Breast Cancer Research and Treatment*, **1985**, 5, 269-76	4.4	54
3	Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer. *Cancer*, **1984**, 54, 2777-94	6.4	46

2	Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. *Hybridoma*, **1984**, 3, 223-32		442
1	Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. *International Journal of Cancer*, **1983**, 31, 543-52	7.5	168